Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Michael Murphree who wrote (3302)	2/25/1998 11:18:00 AM
From: Afaq Sarwar	Read Replies (1) \| Respond to of 3906

Michael Murphree, Thanks for sharing the information. I hope you read the recently filed 8K. It gives in an indirect way an indication of the potential of the technology owned by HVSFD. Afaq Sarwar

To: Michael Murphree who wrote (3302)	3/4/1998 5:41:00 PM
From: Michael Murphree	Respond to of 3906

Wednesday March 4, 11:38 am Eastern Time Company Press Release Harvard Scientific's Patented Lyophilized Liposomal PGE-1 Treatment Proves Stable for 9-Months RENO, Nev.--(BW HealthWire)--March 4, 1998--Harvard Scientific Corp., (OTC BB:HVSF -news) a Nevada corporation, announced Wednesday that results from an ongoing stability study for its patented lyophilized liposomal Prostaglandin E-1 (''LLPGE1'') has proven that it remains stable at room temperature for at least 9-months. LLPGE1 is the active agent used in the company's treatment product for male erectile dysfunction. The company will continue to collaborate with Pyramid Labs in Costa Mesa, Calif. to conduct additional stability tests on LLPGE1 to determine the exact shelf-life for its treatment product. All other intrameatal Prostaglandin E-1 treatment products currently being marketed require refrigeration for long term stability. Dr. Darryl See, the project manager and a company consultant stated: ''The stability data continues to support a product that can be manufactured, shipped and stored in the pharmacy and kept by the patient for an extended period of time precluding the inconvenience and cost of refrigeration. This not only provides a tremendous advantage to us in the laboratory as we continue our research but will be especially convenient for the patient.'' Harvard Scientific Corp. is a biopharmaceutical company that develops products relating to liposomal delivery of Prostaglandin E-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement. The company's patented process allow the Prostaglandin E-1 to be administered as a liquid via a painless delivery system. The company also has developed a topically applied skin treatment for psoriasis and is working with the FDA to establish Phase I clinical trials protocol for that product. Prostaglandin E-1 is a naturally occurring vasodilator originally approved by the U.S. Food and Drug Administration for intravenous infusion in neonates. In 1995, PGE-1 was approved by the FDA for use in Upjohn's Caverject(r), which is administered by needle injection as a treatment for male erectile dysfunction. In November 1996, Vivus Inc [Nasdaq:VVUS - news].'s MUSE(r) delivery system was approved by the FDA. The company believes that its product represents a tremendous treatment advantage over other delivery systems currently being utilized in the industry. From time to time the company may issue forward looking statements which involve risks and uncertainties. This statement may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results could differ and any forward looking statements should be considered accordingly. Contact: I.W. Miller & Co. Ira Miller, 714/833-9001 or Martin E. Janis & Co. Hal Schweig, 312/943-1100 or Harvard Scientific Corp. Michael Snell, 407/324-1606 More Quotes and News: HARVARD SCI CP (OTC BB:HVSF - news) Vivus Inc (Nasdaq:VVUS - news) Related News Categories: biotech, medical/pharmaceutical